Canaccord Genuity Reiterates Buy on Cree (CREE)

Cree (NASDAQ: CREE)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Tuesday.

The analysts wrote, “This morning Cree announced 6-year CFO John Kurtzweil will be stepping down to pursue an opportunity at much smaller Extreme Networks, a provider of network infrastructure. We believe Kurtzweil’s departure highlights a longer-term shift in the business model from chips to lighting fixtures. We will continue to dig into any potential additional reasons for the departure, however we see this announcement as a momentum killer and a reversal in shares is expected in the near term.”

Shares of Cree traded down 6.50% during mid-day trading on Tuesday, hitting $27.20. Cree has a 52 week low of $20.25 and a 52 week high of $33.45. The company has a market cap of $3.145 billion and a P/E ratio of 60.86.

Cree last announced its earnings results on Tuesday, April 17th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.01. The company’s revenue for the quarter was up 29.9% on a year-over-year basis. On average, analysts predict that Cree will post $0.28 earnings per share next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Susquehanna initiated coverage on shares of Cree in a research note to investors on Friday. They set a “positive” rating on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Cree in a research note to investors on Thursday, May 10th. They set a “buy” rating and a $38.00 price target on the stock. Finally, analysts at GARP Research reiterated a “buy” rating on shares of Cree in a research note to investors on Friday, April 20th.

Cree, Inc. (Cree) develops and manufactures semiconductor materials and devices primarily based on silicon carbide (SiC), gallium nitride (GaN) and related compounds.

Latest News

Supreme Court Allows Regulators to Challenge Generic Drug Agreements
Supreme Court Allows Regulators to Challenge Generic Drug Agreements
Car Sales in Europe Hit Record Lows
Car Sales in Europe Hit Record Lows
Woman once on Death Row to Go Free
Woman once on Death Row to Go Free
Bidding for Back Bay Parking Spaces Reaches $560,000
Bidding for Back Bay Parking Spaces Reaches $560,000
Vermont Grappling with Nation’s Second Highest Rate of Lyme disease
Vermont Grappling with Nation’s Second Highest Rate of Lyme disease
Concerns about Origins of Genetically Modified Wheat Affect US White Wheat
Concerns about Origins of Genetically Modified Wheat Affect US White Wheat


Leave a Reply

 
© 2010-2013 Zolmax.com, LLC.
Subscribe Subscribe